Tesamorelin 10mg
$84.00
A stabilized synthetic analog of growth-hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl group, supplied as 10 mg sterile lyophilized powder for in-vitro endocrinology research.
Tested by Freedom Diagnostics TestingHPLC purity + LC-MS identityLot-matched COA on-site
For research use only. This product is a laboratory research chemical. It is not for human or veterinary use, not a drug, supplement, or food, and not intended to diagnose, treat, cure, or prevent any disease. Sold only to qualified researchers and institutions.
What is Tesamorelin?
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44). An N-terminal trans-3-hexenoyl modification protects the peptide from dipeptidyl-peptidase cleavage, giving it markedly greater stability than native GHRH(1-44). It binds the GHRH receptor on pituitary somatotrophs and stimulates the synthesis and pulsatile release of endogenous growth hormone, which is what makes it the reference long-acting GHRH analog in endocrinology research and the active ingredient in the human medicine Egrifta.
Research areas where laboratories buy tesamorelin for in vitro work include GHRH-receptor binding and cAMP-accumulation assays in receptor-expressing cells, somatotroph growth-hormone-release and downstream IGF-1 studies in cell-culture and rodent models, enzymatic-stability comparisons against native GHRH(1-44) and GHRH(1-29), GH-axis pulsatility modeling, and structure-activity studies of N-terminally protected GHRH analogs.
Every lot, independently verified
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
Product Specifications
Molecular Profile
Storage & Handling
Tesamorelin Mechanism of Action
- Binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, stimulating growth-hormone synthesis and release.
- Signals through Gαs / adenylyl-cyclase / cAMP, raising intracellular cAMP and GH gene transcription.
- The N-terminal trans-3-hexenoyl modification confers resistance to dipeptidyl-peptidase cleavage, extending stability relative to native GHRH(1-44).
- Drives downstream IGF-1 production via the GH axis in physiological models.
- Preserves pulsatile GH release, distinguishing it from exogenous GH administration.
- Studied as the reference long-acting GHRH analog in endocrinology research.
Tesamorelin Research Applications
- GHRH-R binding and cAMP-accumulation assays in receptor-expressing cells, where tesamorelin serves as the reference long-acting GHRH analog.
- Somatotroph GH-release and downstream IGF-1 studies in cell-culture and rodent models.
- Enzymatic-stability comparisons against native GHRH(1-44) and GHRH(1-29).
- GH-axis pulsatility modeling under defined conditions.
- Structure-activity studies of N-terminally protected GHRH analogs.
- Comparative secretagogue-synergy experiments with GHRP agonists.
Why Buy Tesamorelin from Koi Peptides?
- Every batch of Koi tesamorelin is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
- Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and endotoxin assay for sterility readiness.
- The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
- Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
References
View all references+
- Mayo, K. E., et al. (1995). Growth hormone-releasing hormone and its receptor. Endocrine Reviews, 16(1), 1–32. doi.org/10.1210/edrv-16-1-1
- Ferdinandi, E. S., et al. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a stabilized analog of GHRH. J. Clinical Endocrinology & Metabolism.
- Guillemin, R., et al. (1982). Growth hormone-releasing factor from a human pancreatic islet tumor. Science, 218(4572), 585–587. doi.org/10.1126/science.6812220
Regulatory Status
FDA StatusTesamorelin is the active ingredient in Egrifta, approved by the FDA in November 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy. Egrifta is an FDA-approved prescription drug product for human therapeutic use under prescription. The research-grade material supplied by Koi Peptides is synthesized independently for in vitro laboratory research only — not formulated, packaged, or labeled for human use, not equivalent to or a substitute for the approved drug product, and not authorized for any human or veterinary indication.
WADA Anti-Doping StatusGHRH analogs and growth-hormone secretagogues are prohibited at all times under section S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances and mimetics). As a stabilized GHRH(1-44) analog that stimulates endogenous growth-hormone release, tesamorelin falls within this prohibited class. Athletes subject to anti-doping rules should treat it accordingly and maintain documentation for any approved medical use.
Compounding Pharmacy StatusKoi Peptides is a chemical research supplier — not a compounding pharmacy or outsourcing facility under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act — and supplies no compounded preparations of any kind. The research-grade material is intended solely for in vitro laboratory study.
For research use only. Not for human or veterinary use. Tesamorelin is supplied to qualified research professionals for in vitro laboratory study. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act. By purchasing, the buyer agrees this material will not be introduced into humans or animals. Misuse may violate federal, state, or local laws.
Be the first to review “Tesamorelin 10mg”
Related products
Reviews
There are no reviews yet.